跳转至内容
Merck
所有图片(1)

主要文件

A0325200

Alcuronium chloride

European Pharmacopoeia (EP) Reference Standard

别名:

N,N′-Diallylnortoxiferinium dichloride

登录查看公司和协议定价
所有图片(1)

About This Item

经验公式（希尔记法）:
C44H50Cl2N4O2
CAS号:
15180-03-7
分子量:
737.80
MDL號碼:
MFCD01711239
分類程式碼代碼:
41116107
NACRES:
NA.24

等級

pharmaceutical primary standard

API 家族

alcuronium

製造商／商標名

EDQM

應用

pharmaceutical (small molecule)

形式

neat

儲存溫度

−20°C

SMILES 字串

[Cl-].[Cl-].[N+]21([C@@H]3C4([C@H]5N(c%11c4cccc%11)\C=C6/[C@@H]7N(c8c(cccc8)C97[C@H]%10[N+](CC9)(C\C(=C\CO)\C/6C%10)CC=C)\C=C/5\C(C3)\C(=C/CO)\C2)CC1)CC=C

InChI

1S/C44H50N4O2.2ClH/c1-3-17-47-19-15-43-35-9-5-7-11-37(35)45-26-34-32-24-40-44(16-20-48(40,18-4-2)28-30(32)14-22-50)36-10-6-8-12-38(36)46(42(34)44)25-33(41(43)45)31(23-39(43)47)29(27-47)13-21-49;;/h3-14,25-26,31-32,39-42,49-50H,1-2,15-24,27-28H2;2*1H/q+2;;/p-2/b29-13-,30-14-,33-25-,34-26-;;/t31?,32?,39-,40-,41-,42-,43?,44?,47?,48?;;/m0../s1

InChI 密鑰

CPYGBGOXCJJJGC-ZHNYPADJSA-L

一般說明

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.
For further information and support please go to the website of the issuing Pharmacopoeia.

應用

Alcuronium chloride EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

包裝

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

其他說明

Sales restrictions may apply.

象形圖

Skull and crossbones
GHS06

訊號詞

Danger

危險聲明

H300

危險分類

Acute Tox. 2 Oral

儲存類別代碼

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

水污染物質分類（WGK）

WGK 3

閃點（°F）

Not applicable

閃點（°C）

Not applicable

从最新的版本中选择一种：

分析证书(COA)

Lot/Batch Number

抱歉，我们目前尚未线上提供该产品的COA。

如需帮助，请联系 客户支持

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

J Jakubík et al.
Molecular pharmacology, 54(5), 899-906 (1998-11-06)
We investigated whether alcuronium, an allosteric modulator of muscarinic acetylcholine receptors, can induce receptor-mediated activation of Go proteins in liposomal membranes incorporating purified M2 receptors and Go proteins and whether its action is affected by the receptor/Go protein (R/Go) ratio.
J Jakubík et al.
Proceedings of the National Academy of Sciences of the United States of America, 93(16), 8705-8709 (1996-08-06)
Ligands that bind to the allosteric-binding sites on muscarinic acetylcholine receptors alter the conformation of the classical-binding sites of these receptors and either diminish or increase their affinity for muscarinic agonists and classical antagonists. It is not known whether the
V Dolezal et al.
British journal of pharmacology, 124(6), 1213-1218 (1998-08-28)
1. Radioligand binding experiments indicate that the affinity of muscarinic receptors for their agonists may be enhanced by allosteric modulators. We have now investigated if brucine can enhance the inhibitory effects of muscarinic receptor agonists on the electrically evoked release
U Holzgrabe et al.
Journal of chemical information and computer sciences, 36(5), 1018-1024 (1996-09-01)
Structurally dissimilar compounds such as alcuronium and the newly synthesized substances derived from the bisbenzyl ether TMB4 and from hexamethonium stabilize antagonist binding to M2-cholinoceptors which is indicative of an allosteric action. In order to propose a hypothesis for the
A Schröter et al.
Naunyn-Schmiedeberg's archives of pharmacology, 362(6), 512-519 (2001-01-04)
Muscarinic M2 acetylcholine receptors contain an allosteric site that is probably located at the entrance of the ligand binding pocket above the orthosteric binding site. With the orthosteric area not occupied, allosteric agents might gain access to this site. The
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门